Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, Besse B.

J Thorac Oncol. 2019 Dec 13. pii: S1556-0864(19)33716-5. doi: 10.1016/j.jtho.2019.11.024. [Epub ahead of print]

PMID:
31843682
2.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L.

Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4.

PMID:
31585938
3.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.

Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B.

J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.

PMID:
31108248
4.

The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin.

Corgnac S, Boutet M, Kfoury M, Naltet C, Mami-Chouaib F.

Front Immunol. 2018 Aug 15;9:1904. doi: 10.3389/fimmu.2018.01904. eCollection 2018. Review.

5.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
6.

A review of bevacizumab in the treatment of malignant pleural mesothelioma.

Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G.

Future Oncol. 2017 Dec;13(28):2537-2546. doi: 10.2217/fon-2017-0307. Epub 2017 Sep 20. Review.

PMID:
29086616
7.

Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation.

Brosseau S, Gounant V, Naltet C, Théou-Anton N, Cazes A, Smonig R, Neuville M, Khalil A, Mikail N, Meignin V, Bergeron A, Zalcman G.

Clin Lung Cancer. 2018 Jan;19(1):e57-e61. doi: 10.1016/j.cllc.2017.07.003. Epub 2017 Aug 3. No abstract available.

PMID:
28844392
8.

Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.

Pluvy J, Brosseau S, Naltet C, Opsomer MA, Cazes A, Danel C, Khalil A, Zalcman G, Gounant V.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700310. doi: 10.1183/13993003.00310-2017. Print 2017 Jul. No abstract available.

9.

[Current knowledge on perioperative treatments of non-small cell lung carcinomas].

Brosseau S, Naltet C, Nguenang M, Gounant V, Mordant P, Milleron B, Castier Y, Zalcman G.

Rev Mal Respir. 2017 Jun;34(6):618-634. doi: 10.1016/j.rmr.2016.12.001. Epub 2017 Jul 12. Review. French.

PMID:
28709816
10.

[Therapeutic advances in lung cancer].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Prat. 2017 Jan;67(1):47-50. French.

PMID:
30512433
11.

[Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Mal Respir. 2016 Oct;33(8):654-657. doi: 10.1016/j.rmr.2016.10.005. French. No abstract available.

PMID:
27968925
12.

Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.

Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G.

Lung Cancer. 2016 Sep;99:162-5. doi: 10.1016/j.lungcan.2016.07.010. Epub 2016 Jul 15.

PMID:
27565934
13.

[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives].

Brosseau S, Naltet C, Gounant V, Zalcman G.

Rev Prat. 2016 Feb;66(2):191-197. French.

PMID:
30512336
14.

[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].

Brosseau S, Oulkhouir Y, Naltet C, Zalcman G.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S27-33. doi: 10.1016/S0007-4551(15)31215-7. Review. French.

PMID:
26118873

Supplemental Content

Loading ...
Support Center